Skip to main content

Table 2 18F-FAMT and 18F-FDG uptake in various tumor types

From: Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET

Histological classification 18F-FAMT 18F-FDG
Median SUVmax (IQR) Median T/N ratio (IQR) Median SUVmax (IQR) Median T/N ratio (IQR)
All gliomas 3.45 (2.58–4.63) 4.08 (2.87–4.76) 6.65 (5.55–10.2) 1.12 (0.86–1.83)
WHO grade II 2.88 (2.04–3.75) 2.85 (2.06–4.28) 5.40 (4.20–8.45) 0.88 (0.75–1.04)
 Diffuse astrocytoma 3.07 2.05 4.10 0.90
 Oligoastrocytoma 2.65 (1.90–4.00) 2.80 (2.11–4.33) 5.10 (4.50–5.80) 0.86 (0.62–0.88)
 Oligodendroglioma 3.60 4.23 10.7 1.39
WHO grade III 4.20 (2.17–5.75) 4.65 (3.50–5.42) 6.55 (6.00–8.28) 1.17 (0.68–2.24)
 Anaplastic astrocytoma 2.63 5.20 6.60 1.22
 Anaplastic oligoastrocytoma 2.68 (1.61–5.15) 4.29 (2.47–5.05) 6.00 (4.93–6.45) 0.71 (0.63–1.17)
 Anaplastic oligodendroglioma 5.70 (4.93–6.40) 5.03 (3.71–6.39) 12.8 (6.70–21.3) 1.91 (1.17–2.75)
WHO grade IV 3.60 (3.05–4.60) 4.09 (3.36–4.92) 9.15 (6.38–11.5) 1.56 (1.11–2.50)
 Glioblastoma 3.60 (3.05–4.60) 4.09 (3.36–4.92) 9.15 (6.38–11.5) 1.56 (1.11–2.50)
  1. IQR interquartile range